文献速递慢性肾脏病肾小球疾病

非糖尿病慢性肾脏病与肾小球疾病中盐皮质激素受体拮抗剂的潜在作用

Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-07-22

综述指出肾小球疾病是CKD和ESKD的主要原因之一,非糖尿病肾小球疾病罕见且高质量临床试验匮乏;当前治疗以控制并发症和针对病因为主,但受异质性和发病机制认识不足限制。SGLT2抑制剂和新型非甾体盐皮质激素受体拮抗剂(如finerenone)具有广泛抗炎抗纤维化作用,在包括CKD在内的心肾疾病中成为有价值治疗选择,ns-MRAs可能改善CKD患者肾脏预后。

要点

  • 非糖尿病肾小球疾病罕见,高质量临床试验少,治疗选择有限
  • 当前治疗包括RAAS抑制剂、他汀、袢利尿剂、抗凝、免疫抑制剂及生活方式调整
  • ns-MRAs(如finerenone)具有抗炎抗纤维化作用,可能改善CKD肾脏预后

核心结论

  • ns-MRAs是未来治疗非糖尿病肾小球疾病值得关注的药物类别,可能减少CKD进展

研究设计与样本

  • 本文为综述,回顾非糖尿病肾小球疾病的当前管理并探索药物治疗最新进展

主要发现

  • 非糖尿病肾小球疾病罕见且高质量临床试验匮乏,异质性和发病机制认识不足限制有效治疗
  • SGLT2抑制剂和ns-MRAs具有广泛抗炎抗纤维化作用,已成为包括CKD在内多种心肾疾病的有价值治疗选择
  • 有证据表明ns-MRAs可能改善不同CKD亚组患者的肾脏预后

临床怎么用

  • 当前治疗应管理水肿、高血压、蛋白尿、高脂血症、高凝和血栓等并发症,并针对病因治疗
  • 治疗选项包括RAAS抑制剂、他汀/非他汀替代、袢利尿剂、抗凝剂、免疫抑制剂及生活方式和饮食调整
  • ns-MRAs(如finerenone)可能作为减少肾小球疾病所致CKD进展的治疗选择

局限性

  • 非糖尿病肾小球疾病罕见,缺乏高质量临床试验
  • 疾病异质性和发病机制认识不足限制有效治疗

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glomerular disease is a leading cause of CKD and ESKD. Although diabetic kidney disease is the most common cause of glomerular disease, nondiabetic causes include malignancy, systemic autoimmune conditions, drug effects, or genetic conditions. Nondiabetic glomerular diseases are rare diseases, with a paucity of high-quality clinical trials in this area. Furthermore, late referral can result in poor patient outcomes. This article reviews the current management of nondiabetic glomerular disease and explores the latest developments in drug treatment in this area. Current treatment of nondiabetic glomerular disease aims to manage complications (edema, hypertension, proteinuria, hyperlipidemia, hypercoagulability, and thrombosis) as well as target the underlying cause of glomerular disease. Treatment options include renin-angiotensin-aldosterone system inhibitors, statins/nonstatin alternatives, loop diuretics, anticoagulation agents, immunosuppressives, and lifestyle and dietary modifications. Effective treatment of nondiabetic glomerular disease is limited by heterogeneity and a lack of understanding of the disease pathogenesis. Sodium-glucose cotransporter-2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs, such as finerenone), with their broad anti-inflammatory and antifibrotic effects, have emerged as valuable therapeutic options for a range of cardiorenal conditions, including CKD. ns-MRAs are an evolving drug class of particular interest for the future treatment of nondiabetic glomerular disease, and there is evidence that these agents may improve kidney prognosis in various subgroups of patients with CKD. The benefits offered by ns-MRAs may present an opportunity to reduce the progression of CKD from a spectrum of glomerular disease. Several novel ns-MRA are in clinical development for both diabetic and nondiabetic CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024. PMID: 39037799. doi:10.2215/CJN.0000000000000540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。